



BioArctic in 3 minutes

New era, with a focus on growth

BioArctic is an innovative Swedish biopharma company with the ambition to fundamentally change the treatment of serious neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and ALS. BioArctic has developed the world's first disease-modifying treatment for Alzheimer's disease, and most of the company's other drug candidates are built on the same principle: selective antibodies against misfolded proteins in the brain. In parallel, the company has developed the BrainTransporter technology, which changes how different types of drugs can be transported into the brain. With an approved drug, several new global agreements in place, and a clearly anchored growth strategy, BioArctic has an increased focus on accelerating research that can improve the lives of even more people. BioArctic's sustainability agenda is based on the principle that its innovations should contribute to better health.



Goal for 2030

BioArctic's goal long-term is to become Sweden's next major biopharma company. The goal for 2030 is that:

- Leqembi becomes an established treatment for Alzheimer's disease
- The pipeline expands, with projects in all phases of development
- More successful global partnerships are established
- The company is sustainably profitable, with recurring dividends

53 countries

Leqembi is marketed globally by Eisai and in partnership with BioArctic in the Nordic region. As of March 31, 2026, Leqembi has been approved for intravenous treatment in 53 countries. The drug has also been approved for less frequent intravenous maintenance treatment in a number of markets, and application processes for subcutaneous treatment with autoinjectors are underway.



The first drug to slow Alzheimer's disease

Leqembi is the world's first approved drug for early Alzheimer's disease that slows the disease progression and reduces cognitive decline. Lecanemab, the original antibody, was invented by BioArctic, and has been outlicensed to the Japanese pharmaceutical company Eisai since 2007. Leqembi was launched in the US and Japan in 2023, and in China in 2024. The drug was approved in the EU in 2025. BioArctic is entitled to royalties based on global sales, milestone payments and co-promotion revenue in the Nordic region.




The BrainTransporter technology increases concentration of drugs in the brain

One challenge when developing antibodies or other drugs against diseases of the central nervous system is obtaining a sufficiently high concentration and distribution of the drug in the brain. BioArctic's platform technology, BrainTransporter, has shown in preclinical trials that it can greatly increase the amount of antibodies entering the brain, raising the concentration by up to 70 times. This high concentration has the potential to improve treatment efficacy at a lower dose while reducing the risk of side effects. BioArctic uses this technology to develop the company's in-house drug candidates, and it is also available to other companies through licensing agreements. Currently, there are three agreements for BrainTransporter.




Vision

A world where science defeats severe brain diseases.



Antibodies against misfolded proteins

BioArctic's co-founder Lars Lannfelt's groundbreaking idea in Alzheimer's disease has proven applicable to several neurodegenerative diseases. It is now known that misfolded proteins in the central nervous system also lie behind disorders such as Parkinson's disease, Lewy body dementia, multiple system atrophy, ALS and Huntington's disease. At present, BioArctic specializes in developing selective antibodies that assist the body to remove the misfolded proteins that cause these diseases, and the initial research has grown into a broad pipeline.



BioArctic's sustainability agenda is based on the principle that the company's innovations should contribute to better health.

Mission

BioArctic is an innovative biopharmaceutical company in precision neurology. Through world-leading research and collaborations, we create, develop and deliver innovative treatments for patients with severe brain diseases.

131 employees

BioArctic has operations in Sweden, Norway, Denmark and Finland. Of the 131 employees at the end of December 2025, 69 percent work in R&D.